RCKT vs. RNA, KDNY, CVAC, CINC, TVTX, SNDX, AUPH, ARVN, VRNA, and DICE
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Avidity Biosciences (RNA), Chinook Therapeutics (KDNY), CureVac (CVAC), CinCor Pharma (CINC), Travere Therapeutics (TVTX), Syndax Pharmaceuticals (SNDX), Aurinia Pharmaceuticals (AUPH), Arvinas (ARVN), Verona Pharma (VRNA), and DICE Therapeutics (DICE). These companies are all part of the "pharmaceutical preparations" industry.
Rocket Pharmaceuticals vs.
Avidity Biosciences (NASDAQ:RNA) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.
Rocket Pharmaceuticals received 233 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 73.20% of users gave Rocket Pharmaceuticals an outperform vote while only 62.89% of users gave Avidity Biosciences an outperform vote.
Avidity Biosciences currently has a consensus target price of $44.60, suggesting a potential upside of 122.00%. Rocket Pharmaceuticals has a consensus target price of $52.58, suggesting a potential upside of 233.02%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Avidity Biosciences.
Rocket Pharmaceuticals has a net margin of 0.00% compared to Avidity Biosciences' net margin of -1,886.33%. Avidity Biosciences' return on equity of -40.82% beat Rocket Pharmaceuticals' return on equity.
93.2% of Rocket Pharmaceuticals shares are owned by institutional investors. 6.6% of Avidity Biosciences shares are owned by company insiders. Comparatively, 33.7% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Rocket Pharmaceuticals had 13 more articles in the media than Avidity Biosciences. MarketBeat recorded 15 mentions for Rocket Pharmaceuticals and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.27 beat Rocket Pharmaceuticals' score of 0.12 indicating that Avidity Biosciences is being referred to more favorably in the media.
Avidity Biosciences has higher revenue and earnings than Rocket Pharmaceuticals. Avidity Biosciences is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Rocket Pharmaceuticals beats Avidity Biosciences on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
